Reference number
1736-H

SPECIALTY QUANTITY LIMIT PROGRAM

ACTEMRA (tocilizumab)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Actemra (tocilizumab) 162 mg per 0.9 mL prefilled syringe for subcutaneous injection	4 syringes per 28 days	• **RA (adult), weight < 100 kg**: 162 mg every other week, followed by an increase to every week based on clinical response • **RA (adult), weight ≥ 100 kg**: 162 mg every week • **PJIA, weight < 30 kg**: 162 mg every 3 weeks • **PJIA, weight ≥ 30 kg**: 162 mg every 2 weeks • **SJIA, weight < 30 kg**: 162 mg every 2 weeks • **SJIA, weight ≥ 30 kg**: 162 mg every week • **Giant cell arteritis**: 162 mg every week (can be given every other week based on clinical considerations)
Actemra (tocilizumab) 162 mg per 0.9 mL ACTPen autoinjector for subcutaneous injection	4 autoinjectors per 28 days	
Actemra (tocilizumab) 80 mg per 4 mL single-use vial	20 mL (5 vials) per 28 days	• **RA (adult)**: 4 mg per kg every 4 weeks followed by an increase to 8 mg per kg every 4 weeks based on clinical response, up to 800 mg per infusion • **PJIA, weight < 30 kg**: 10 mg per kg every 4 weeks • **PJIA, weight ≥ 30 kg**: 8 mg per kg every 4 weeks • **SJIA, weight < 30 kg**: 12 mg per kg every 2 weeks • **SJIA, weight ≥ 30 kg**: 8 mg per kg every 2 weeks
Actemra (tocilizumab) 200 mg per 10 mL single-use vial	40 mL (4 vials) per 14 days	
Actemra (tocilizumab) 400 mg per 20 mL single-use vial	40 mL (2 vials) per 14 days	

Abbreviations: RA = rheumatoid arthritis; PJIA = polyarticular juvenile idiopathic arthritis; SJIA = systemic juvenile idiopathic arthritis.

III. REFERENCE

1. Actemra [package insert]. South San Francisco, CA: Genentech, Inc.; November 2018.